J&J Halts Sirukumab Development, Talacotuzumab Trial

Johnson & Johnson said today it has ended development of the rheumatoid arthritis candidate sirukumab, and halted a Phase II/III trial of the acute myeloid leukemia (AML) candidate talacotuzumab—both of which the pharma giant had touted as potential blockbusters just five months ago.Sirukumab had been under development by J&J’s Janssen Biotech for moderate-to-severely active rheumatoid arthritis, but was rejected on September 22 by the FDA, which instead issued a complete res